Kura Oncology (NASDAQ:KURA) Issues Earnings Results

Kura Oncology (NASDAQ:KURA) issued its quarterly earnings results on Wednesday. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.43, Zacks reports.

Kura Oncology Trading Down 1.4 %

NASDAQ KURA traded down $0.11 on Wednesday, hitting $7.77. The company’s stock had a trading volume of 695,635 shares, compared to its average volume of 1,618,769. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. Kura Oncology has a 52-week low of $6.98 and a 52-week high of $24.17. The firm has a market cap of $604.23 million, a P/E ratio of -3.29 and a beta of 0.78. The company’s 50-day simple moving average is $8.22 and its 200 day simple moving average is $13.96.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the company. JMP Securities reissued a “market outperform” rating and set a $28.00 price objective on shares of Kura Oncology in a report on Thursday, February 6th. TD Cowen reissued a “buy” rating on shares of Kura Oncology in a research note on Thursday, November 21st. Jefferies Financial Group cut their price objective on shares of Kura Oncology from $32.00 to $28.00 and set a “buy” rating for the company in a research note on Thursday, November 21st. Wedbush lifted their target price on shares of Kura Oncology from $34.00 to $36.00 and gave the stock an “outperform” rating in a research report on Thursday, February 6th. Finally, StockNews.com downgraded shares of Kura Oncology from a “hold” rating to a “sell” rating in a research note on Wednesday, November 20th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Kura Oncology has a consensus rating of “Moderate Buy” and an average target price of $27.13.

Insider Activity at Kura Oncology

In other Kura Oncology news, insider Mollie Leoni sold 4,963 shares of the company’s stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.81. Following the completion of the transaction, the insider now directly owns 88,253 shares in the company, valued at approximately $694,551.11. This represents a 5.32 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Thomas James Doyle sold 4,949 shares of the firm’s stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $38,948.63. Following the completion of the sale, the senior vice president now directly owns 88,193 shares of the company’s stock, valued at approximately $694,078.91. This represents a 5.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 11,729 shares of company stock worth $92,307 over the last quarter. 5.50% of the stock is owned by corporate insiders.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.